Adial Pharmaceuticals, Inc. Deferred Tax Liabilities, Intangible Assets
Adial Pharmaceuticals, Inc. (ADIL) had Deferred Tax Liabilities, Intangible Assets of $530 as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2026-03-05
- 2025-12-31: Deferred Tax Liabilities, Intangible Assets $530.00.
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $495.00.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $437.00.
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $384.00.
| Period end | Deferred Tax Liabilities, Intangible Assets |
|---|---|
| 2025-12-31 | $530.00 10-K · filed 2026-03-05 |
| 2024-12-31 | $495.00 10-K · filed 2026-03-05 |
| 2023-12-31 | $437.00 10-K · filed 2025-03-04 |
| 2022-12-31 | $384.00 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |